CoChat

Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis

Open access
Rubinstein, Andrea L., Carpenter, Diane M. · 2017 · Pain Medicine
Cited by 44

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objective. Androgen deficiency is common among men who use opioids daily for chronic pain. In previous studies, we found that long-acting opioids are associated with greater odds of androgen suppression than equipotent doses of short-acting opioids. Here we examined whether specific commonly prescribed opioids were associated with greater odds of androgen deficiency compared to hydrocodone. Design. Retrospective cohort study. Setting and Patients. Within a large, integrated health care delivery system, this study was comprised of men ages 18–80 on a stable regimen of a single opioid for chronic non-cancer pain. Methods. Morning serum total testosterone levels were measured in subjects prescribed one opioid for at least 90 days. The association between individual opioids and androgen deficiency was assessed with logistic regression, controlling for dose, obesity, age, hypertension, hyperlipidemia, and diabetes, using hydrocodone as a referent. Results. This study included 1,159 men. Men on fentanyl (odds ratio [OR] 25.7, 95% CI 2.82–234.97), methadone (OR 7.33, 95% CI 3.29–16.33), or oxycodone (OR 3.15, 95% CI 1.87–5.33) were more likely to be androgen deficient than men on hydrocodone. Increases in dose affected the odds of androgen deficiency differently for different opioids. Increased doses of hydrocodone (OR 1.18 per 10-mg increase in drug, 95% CI 1.09–1.28) and oxycodone (OR 1.01, 95% CI 1.00–1.02) were associated with increased odds of androgen deficiency. Conclusions. Our results suggest that certain opioids are associated with increased odds of androgen deficiency compared with hydrocodone. Transdermal fentanyl, methadone and oxycodone were associated with higher odds of androgen deficiency than hydrocodone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/pm/pnw182

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 21

  1. Grosset, 2005, Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: Two randomized controlled trials, J Pain Symptom Manage, 29, 584, 10.1016/j.jpainsymman.2004.10.008 · DOI
  2. Hale, 1999, Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain, Clin J Pain, 15, 179, 10.1097/00002508-199909000-00004 · DOI · Paper page
  3. Stambaugh, 2001, Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients, J Clin Pharmacol, 41, 500, 10.1177/00912700122010375 · DOI · Paper page
  4. Wilsey, 2009, Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: A randomized cross-over trial, Pharmacol Biochem Behav, 94, 98, 10.1016/j.pbb.2009.07.014 · DOI
  5. Mattia, 2012, Non-analgesic effects of opioids: The interaction of opioids with bone and joints, Curr Pharm Des, 18, 6005, 10.2174/138161212803582487 · DOI
  6. Tuck, 2009, Testosterone, bone and osteoporosis, Front Hormone Res, 37, 123, 10.1159/000176049 · DOI · Paper page
  7. Rubinstein, 2013, Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids, Clin J Pain, 29, 840, 10.1097/AJP.0b013e31827c7b5d · DOI · Paper page
  8. Pereira, 2001, Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing, J Pain Symptom Manage, 22, 672, 10.1016/S0885-3924(01)00294-9 · DOI · Paper page
  9. Kuczmarski, 1997, Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994), Obesity Res, 5, 542, 10.1002/j.1550-8528.1997.tb00575.x · DOI · Paper page
  10. Moffet, 2009, Cohort profile: The Diabetes Study of Northern California (DISTANCE)–Objectives and design of a survey follow-up study of social health disparities in a managed care population, Int J Epidemiol, 38, 38, 10.1093/ije/dyn040 · DOI · Paper page
  11. Jones, 2010, Effects of testosterone on Type 2 diabetes and components of the metabolic syndrome, J Diabetes, 2, 146, 10.1111/j.1753-0407.2010.00085.x · DOI · Paper page
  12. Kang, 2013, Beyond the male sex hormone: Deciphering the metabolic and vascular actions of testosterone, J Endocrinol, 217, C1, 10.1530/JOE-13-0052 · DOI
  13. Muraleedharan, 2010, Testosterone and the metabolic syndrome, Ther Adv Endocrinol Metabol, 1, 207, 10.1177/2042018810390258 · DOI
  14. Kelly, 2013, Testosterone: A metabolic hormone in health and disease, J Endocrinol, 217, R25, 10.1530/JOE-12-0455 · DOI · Paper page
  15. Mendelson, 1975, Effects of heroin and methadone on plasma cortisol and testosterone, J Pharmacol Exp Ther, 195, 296, 10.1016/S0022-3565(25)30341-1 · DOI · Paper page
  16. Azizi, 1973, Decreased serum testosterone concentration in male heroin and methadone addicts, Steroids, 22, 467, 10.1016/0039-128X(73)90002-0 · DOI
  17. Cicero, 1975, Function of the male sex organs in heroin and methadone users, N Engl J Med, 292, 882, 10.1056/NEJM197504242921703 · DOI · Paper page
  18. Roberts, 2002, Sex hormone suppression by intrathecal opioids: A prospective study, Clin J Pain, 18, 144, 10.1097/00002508-200205000-00002 · DOI · Paper page
  19. Kelly, 2013, Testosterone: A vascular hormone in health and disease, J Endocrinol, 217, R47, 10.1530/JOE-12-0582 · DOI · Paper page
  20. Baumblatt, 2014, High-risk use by patients prescribed opioids for pain and its role in overdose deaths, JAMA Int Med, 174, 796, 10.1001/jamainternmed.2013.12711 · DOI · Paper page
  21. Pedersen, 2014, Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review, Acta Anaesthesiol Scand, 58, 390, 10.1111/aas.12279 · DOI

Cited by

See all 44

Metadata

Authors
Rubinstein, A. L., & Carpenter, D. M.
Venue
Pain Medicine
Published
2017-04-01
Volume
18
Issue
4
Pages
637-644
ISSN
  • 1526-2375 (ISSN-L)
  • 1526-4637
OpenAlex
W2518204729
Cited by
44
References
7
FWCI
3.75
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. https://app.cochat.ai/papers/10.1093/pm/pnw182
The paper
Rubinstein, A. L., & Carpenter, D. M. (2017). Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. Pain Medicine. https://doi.org/10.1093/pm/pnw182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.